Paratek Pharmaceuticals Inc  

(Public, NASDAQ:PRTK)   Watch this stock  
Find more results for NASDAQ:TSPT
+0.21 (1.60%)
Aug 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.07 - 13.38
52 week 12.05 - 28.74
Open 13.23
Vol / Avg. 0.00/167,490.00
Mkt cap 311.70M
P/E     -
Div/yield     -
EPS -6.00
Shares 22.63M
Beta 0.23
Inst. own 88%
Nov 10, 2016
Q3 2016 Paratek Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 7, 2016
Paratek Pharmaceuticals Inc at Robert W Baird Global Healthcare Conference - 4:55PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Paratek Pharmaceuticals Inc Earnings Release
Aug 4, 2016
Q2 2016 Paratek Pharmaceuticals Inc Earnings Call
Jun 22, 2016
Paratek Pharmaceuticals Inc at JMP Securities Life Sciences Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -85.87% -55.38%
Return on average equity -135.27% -72.14%
Employees 41 -
CDP Score - -


75 Park Plz Ste 4
BOSTON, MA 02116-3934
United States - Map
+1-617-8076600 (Phone)
+1-617-2750039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

Officers and directors

Michael F. Bigham CPA Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Evan Loh M.D. President, Chief Medical Officer, Director
Age: 56
Bio & Compensation  - Reuters
Douglas W. Pagan Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
William M. Haskel Senior Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Regina D. Paglia Senior Vice President - Human Resources
Bio & Compensation  - Reuters
Rajesh Padmanabhan Vice President - Information Technology
Bio & Compensation  - Reuters
Stephen Villano M.D. Vice President - Clinical and Medical Affairs
Bio & Compensation  - Reuters
Adam Woodrow Vice President and Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Timothy R. Franson M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard J. Lim Independent Director
Age: 43
Bio & Compensation  - Reuters